Veterinary Medicines Information website

Poulvac IBMM + ARK lyophilisate for oculonasal suspension for chickens

Authorised
  • Infectious bronchitis virus, type 793/B, strain Arkansas 3168, Live
  • Infectious bronchitis virus, type Massachusetts, strain 1263, Live
Download as PDF

Product identification

Medicine name:
Poulvac IBMM + ARK lyophilisate for oculonasal suspension for chickens
Active substance:
  • Infectious bronchitis virus, type 793/B, strain Arkansas 3168, Live
  • Infectious bronchitis virus, type Massachusetts, strain 1263, Live
Target species:
  • Chicken
Route of administration:
  • Oculonasal use

Product details

Active substance and strength:
  • Infectious bronchitis virus, type 793/B, strain Arkansas 3168, Live
    3.30
    log 10 50% embryo infective dose
    /
    1.00
    Dose
  • Infectious bronchitis virus, type Massachusetts, strain 1263, Live
    3.30
    log 10 50% embryo infective dose
    /
    1.00
    Dose
Pharmaceutical form:
  • Lyophilisate for oculonasal suspension
Withdrawal period by route of administration:
  • Oculonasal use
    • Chicken
      • All relevant tissues
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI01AD07
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Belgium
Available in:
  • Belgium
Package description:
  • Hydrolytic type I glass vials closed with butyl rubber stopper and sealed with an aluminium crimp cap. containing 10 x 10,000 doses (box of 10 vials).
  • Hydrolytic type I glass vials closed with butyl rubber stopper and sealed with an aluminium crimp cap. containing 10 x 5,000 doses (box of 10 vials).
  • Hydrolytic type I glass vials with a butyl rubber (Ph Eur) stopper and aluminium cap of 6 ml containing 1,000 doses (box of 10 vials).

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Zoetis Belgium
Marketing authorisation date:
Manufacturing sites for batch release:
  • Zoetis Manufacturing & Research Spain S.L.
Responsible authority:
  • Federal Agency For Medicines And Health Products
Authorisation number:
  • BE-V259375
Date of authorisation status change:
Reference member state:
  • Netherlands
Procedure number:
  • NL/V/0258/001
Concerned member states:
  • Belgium
  • Greece
  • Ireland
  • Italy
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
French (PDF)
Published on: 9/07/2026
Download
Dutch (PDF)
Published on: 9/07/2026
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
French (PDF)
Published on: 9/07/2026
Download
German (PDF)
Published on: 9/07/2026
Download
Dutch (PDF)
Published on: 9/07/2026
Download

Labelling

This document does not exist in this language (English). You can find it in another language below.
French (PDF)
Published on: 9/07/2026
Download
German (PDF)
Published on: 9/07/2026
Download
Dutch (PDF)
Published on: 9/07/2026
Download

Combined File of all Documents

English (PDF)
Published on: 11/02/2026
Updated on: 14/03/2026
Download